KRTX Karuna Therapeutics Inc

Price (delayed)

$115.18

Market cap

$3.39B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.36

Enterprise value

$3.04B

Sector: Healthcare
Industry: Biotechnology

Highlights

The equity has surged by 73% since the previous quarter and by 52% year-on-year
The debt has declined by 10% year-on-year and by 8% since the previous quarter
KRTX's EPS has surged by 98% year-on-year but it is down by 30% since the previous quarter
The company's quick ratio has surged by 83% QoQ but it fell by 40% YoY
The net income has plunged by 123% YoY and by 32% from the previous quarter

Key stats

What are the main financial stats of KRTX
Market
Shares outstanding
29.46M
Market cap
$3.39B
Enterprise value
$3.04B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$90.35M
EBITDA
-$90.11M
Free cash flow
-$83.08M
Per share
EPS
-$3.36
Free cash flow per share
-$2.99
Book value per share
$21.67
Revenue per share
$0
TBVPS
$21.35
Balance sheet
Total assets
$593.26M
Total liabilities
$8.35M
Debt
$2.48M
Equity
$584.91M
Working capital
$583.39M
Liquidity
Debt to equity
0
Current ratio
89.02
Quick ratio
86.23
Net debt/EBITDA
3.9
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-21.5%
Return on equity
-21.9%
Return on invested capital
-33.3%
Return on capital employed
-15.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRTX stock price

How has the Karuna Therapeutics stock price performed over time
Intraday
3.06%
1 week
7.14%
1 month
-1.48%
1 year
36.78%
YTD
13.38%
QTD
-4.2%

Financial performance

How have Karuna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$91.72M
Net income
-$90.39M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 123% YoY and by 32% from the previous quarter
The operating income has dropped by 109% year-on-year and by 28% since the previous quarter

Growth

What is Karuna Therapeutics's growth rate over time

Valuation

What is Karuna Therapeutics stock price valuation
P/E
N/A
P/B
5.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KRTX's EPS has surged by 98% year-on-year but it is down by 30% since the previous quarter
The equity has surged by 73% since the previous quarter and by 52% year-on-year
The price to book (P/B) is 22% less than the last 4 quarters average of 6.8

Efficiency

How efficient is Karuna Therapeutics business performance
The return on assets has declined by 36% year-on-year and by 16% since the previous quarter
Karuna Therapeutics's ROIC has decreased by 28% from the previous quarter and by 14% YoY
Karuna Therapeutics's return on equity has decreased by 20% YoY and by 16% QoQ

Dividends

What is KRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRTX.

Financial health

How did Karuna Therapeutics financials performed over time
The company's quick ratio has surged by 83% QoQ but it fell by 40% YoY
Karuna Therapeutics's current ratio has surged by 77% QoQ but it has decreased by 39% YoY
The debt is 100% smaller than the equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
The equity has surged by 73% since the previous quarter and by 52% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.